secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2023-03-17T23:59:59+00:00
Accession:  0001628280-23-008386
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda appoints Dr. Tage Honoré to Board, expanding from 5 to 6 directors
------------------------------------------------------------------------

- Board expanded to six members, five independent; Dr. Honoré appointed as Class I director.
- Initial equity grant $337,500 (50% options, 50% RSUs) + $50k annual retainer.
- Annual equity award $225,000 after each annual meeting; change-of-control acceleration.
- Dr. Honoré held exec roles at Novo Nordisk, Novartis, Purdue; discovered AMPA receptors.
- No related party transactions; independent under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828023008386/0001628280-23-008386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828023008386/vnda-20230315.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-008386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer